Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 May 15;32(5):280.
doi: 10.3390/curroncol32050280.

Precision Medicine for Pediatric Glioma and NF1-Associated Tumors: The Role of Small Molecule Inhibitors

Samuele Renzi  1   2 , Julie Bennett  3   4   5 , Nirav Thacker  6 , Chantel Cacciotti  7
Affiliations
Review

Precision Medicine for Pediatric Glioma and NF1-Associated Tumors: The Role of Small Molecule Inhibitors

Samuele Renzi et al. Curr Oncol. .

Abstract

Pediatric gliomas encompass the most common brain tumor in children and are subdivided into pediatric low-grade gliomas (pLGGs) and pediatric high-grade gliomas (pHGGs). The era of molecular diagnosis has shifted the treatment paradigms and management of these patients. RAS/MAPK pathway alterations serve as the driver in the majority of pLGGs, a subset of pHGG and NF1-related plexiform neurofibromas (PNs). The role of small molecule inhibitors in the treatment of these tumors has evolved in the past decade, facilitated through multiple clinical trials and moving into earlier stages of treatment. Although these developments hold promise, questions remain regarding targeted therapy, the long-term toxicities, the duration of treatment and the potential effects on the natural history of the tumor behavior.

Keywords: BRAF inhibitor; FGFR inhibitor; MEK inhibitor; NF-1; Pan-RAF inhibitor; TRK inhibitor; glioma; mTOR inhibition; plexiform neurofibroma; tuberous sclerosis.

PubMed Disclaimer

Conflict of interest statement

The authors have no relevant conflicts of interest to disclose.

Figures

Figure 1
Figure 1
RAS/MAPK and PI3K pathways with relevant targeted therapy agents.
See this image and copyright information in PMC

References

    1. Louis D.N., Perry A., Wesseling P., Brat D.J., Cree I.A., Figarella-Branger D., Hawkins C., Ng H.K., Pfister S.M., Reifenberger G., et al. The 2021 WHO Classification of Tumors of the Central Nervous System: A summary. Neuro Oncol. 2021;23:1231–1251. doi: 10.1093/neuonc/noab106. - DOI - PMC - PubMed
    1. Ostrom Q.T., Gittleman H., Liao P., Vecchione-Koval T., Wolinsky Y., Kruchko C., Barnholtz-Sloan J.S. CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014. Neuro Oncol. 2017;19:v1–v88. doi: 10.1093/neuonc/nox158. - DOI - PMC - PubMed
    1. Merchant T.E., Conklin H.M., Wu S., Lustig R.H., Xiong X. Late effects of conformal radiation therapy for pediatric patients with low-grade glioma: Prospective evaluation of cognitive, endocrine, and hearing deficits. J. Clin. Oncol. 2009;27:3691–3697. doi: 10.1200/JCO.2008.21.2738. - DOI - PMC - PubMed
    1. Packer R.J., Lange B., Ater J., Nicholson H.S., Allen J., Walker R., Prados M., Jakacki R., Reaman G., Needles M.N. Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. J. Clin. Oncol. 1993;11:850–856. doi: 10.1200/JCO.1993.11.5.850. - DOI - PubMed
    1. Ryall S., Zapotocky M., Fukuoka K., Nobre L., Guerreiro Stucklin A., Bennett J., Siddaway R., Li C., Pajovic S., Arnoldo A., et al. Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas. Cancer Cell. 2020;37:569–583.E5. doi: 10.1016/j.ccell.2020.03.011. - DOI - PMC - PubMed